These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26033708)

  • 41. Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer - Preliminary Results From the MENOCOR Study.
    Passildas J; Collard O; Savoye AM; Dohou J; Ginzac A; Thivat E; Durando X; Kwiatkowski F; Penault-Llorca F; Abrial C; Mouret-Reynier MA
    Clin Breast Cancer; 2019 Feb; 19(1):e74-e84. PubMed ID: 30448088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
    Del Mastro L; Fabi A; Mansutti M; De Laurentiis M; Durando A; Merlo DF; Bruzzi P; La Torre I; Ceccarelli M; Kazeem G; Marchi P; Boy D; Venturini M; De Placido S; Cognetti F
    BMC Cancer; 2013 Mar; 13():164. PubMed ID: 23537313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
    Hatschek T; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Lindh B; Loman N; Malmberg M; Rotstein S; Söderberg M; Sundquist M; Walz TM; Hellström M; Svensson H; Aström G; Brandberg Y; Carstensen J; Fernö M; Bergh J
    Breast Cancer Res Treat; 2012 Feb; 131(3):939-47. PubMed ID: 22094937
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; Murillo SM; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G;
    Ann Oncol; 2018 Mar; 29(3):661-668. PubMed ID: 29228091
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran.
    Hatam N; Askarian M; Javan-Noghabi J; Ahmadloo N; Mohammadianpanah M
    Asian Pac J Cancer Prev; 2015; 16(18):8265-70. PubMed ID: 26745071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.
    Sherrill B; Di Leo A; Amonkar MM; Wu Y; Zvirbule Z; Aziz Z; Bines J; Gomez HL
    Curr Med Res Opin; 2010 Apr; 26(4):767-75. PubMed ID: 20095796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
    Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
    Geater SL; Xu CR; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Palmer M; Shi Y; Lungershausen J; Wu YL
    J Thorac Oncol; 2015 Jun; 10(6):883-9. PubMed ID: 25933111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study.
    Karamouzis MV; Ioannidis G; Rigatos G
    Eur J Cancer Care (Engl); 2007 Sep; 16(5):433-8. PubMed ID: 17760930
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
    Roy V; LaPlant BR; Gross GG; Bane CL; Palmieri FM;
    Ann Oncol; 2009 Mar; 20(3):449-53. PubMed ID: 19087987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
    Zhang J; Lin Y; Sun XJ; Wang BY; Wang ZH; Luo JF; Wang LP; Zhang S; Cao J; Tao ZH; Wu J; Shao ZM; Yang WT; Hu XC
    Ann Oncol; 2018 Aug; 29(8):1741-1747. PubMed ID: 29905759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
    Svensson H; Hatschek T; Johansson H; Einbeigi Z; Brandberg Y
    Med Oncol; 2012 Jun; 29(2):432-8. PubMed ID: 21298494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.
    Maione P; Perrone F; Gallo C; Manzione L; Piantedosi F; Barbera S; Cigolari S; Rosetti F; Piazza E; Robbiati SF; Bertetto O; Novello S; Migliorino MR; Favaretto A; Spatafora M; Ferraù F; Frontini L; Bearz A; Repetto L; Gridelli C; Barletta E; Barzelloni ML; Iaffaioli RV; De Maio E; Di Maio M; De Feo G; Sigoriello G; Chiodini P; Cioffi A; Guardasole V; Angelini V; Rossi A; Bilancia D; Germano D; Lamberti A; Pontillo V; Brancaccio L; Renda F; Romano F; Esani G; Gambaro A; Vinante O; Azzarello G; Clerici M; Bollina R; Belloni P; Sannicolò M; Ciuffreda L; Parello G; Cabiddu M; Sacco C; Sibau A; Porcile G; Castiglione F; Ostellino O; Monfardini S; Stefani M; Scagliotti G; Selvaggi G; De Marinis F; Martelli O; Gasparini G; Morabito A; Gattuso D; Colucci G; Galetta D; Giotta F; Gebbia V; Borsellino N; Testa A; Malaponte E; Capuano MA; Angiolillo M; Sollitto F; Tirelli U; Spazzapan S; Adamo V; Altavilla G; Scimone A; Hopps MR; Tartamella F; Ianniello GP; Tinessa V; Failla G; Bordonaro R; Gebbia N; Valerio MR; D'Aprile M; Veltri E; Tonato M; Darwish S; Romito S; Carrozza F; Barni S; Ardizzoia A; Corradini GM; Pavia G; Belli M; Colantuoni G; Galligioni E; Caffo O; Labianca R; Quadri A; Cortesi E; D'Auria G; Fava S; Calcagno A; Luporini G; Locatelli MC; Di Costanzo F; Gasperoni S; Isa L; Candido P; Gaion F; Palazzolo G; Nettis G; Annamaria A; Rinaldi M; Lopez M; Felletti R; Di Negro GB; Rossi N; Calandriello A; Maiorino L; Mattioli R; Celano A; Schiavon S; Illiano A; Raucci CA; Caruso M; Foa P; Tonini G; Curcio C; Cazzaniga M
    J Clin Oncol; 2005 Oct; 23(28):6865-72. PubMed ID: 16192578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
    Allouache D; Gawande SR; Tubiana-Hulin M; Tubiana-Mathieu N; Piperno-Neumann S; Mefti F; Bozec L; Genot JY
    BMC Cancer; 2005 Nov; 5():151. PubMed ID: 16316459
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
    Fernández A; Salgado M; García A; Buxò E; Vera R; Adeva J; Jiménez-Fonseca P; Quintero G; Llorca C; Cañabate M; López LJ; Muñoz A; Ramírez P; González P; López C; Reboredo M; Gallardo E; Sanchez-Cánovas M; Gallego J; Guillén C; Ruiz-Miravet N; Navarro-Pérez V; De la Cámara J; Alés-Díaz I; Pazo-Cid RA; Carmona-Bayonas A
    BMC Cancer; 2018 Nov; 18(1):1185. PubMed ID: 30497432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Worsening of rest-activity circadian rhythm and quality of life in female breast cancer patients along progression of chemotherapy cycles.
    Sultan A; Choudhary V; Parganiha A
    Chronobiol Int; 2017; 34(5):609-623. PubMed ID: 28276853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.